NCT00436904View on ClinicalTrials.gov

Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

November 30, 2011

Conditions

Leukemia

Interventions

DRUG

Alemtuzumab

30 mg Monday, Wednesday, and Friday x 5 weeks

DRUG

Rituximab

375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER